Keytruda Monotherapy Reduced Progression or Death Risk by 43%
The headline reports a 43% reduction for certain patients with advanced or recurrent endometrial cancer with mismatch repair-deficient tumors versus chemotherapy.
The headline reports a 43% reduction for certain patients with advanced or recurrent endometrial cancer with mismatch repair-deficient tumors versus chemotherapy.